Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Breast 1

Conditions

Breast Neoplasms 3Uterine Neoplasms 1Triple Negative Breast Neoplasms 1Pathologic Complete Response 1Ovarian Neoplasms 1Neoplasms 1Hemangiosarcoma 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Desmoid Tumors 1Carcinoma, Intraductal, Noninfiltrating 1

Interventions

Paclitaxel 6pembrolizumab 3Cisplatin 3Carboplatin 3Biopsy 3adavosertib 2Trastuzumab 2Magnetic Resonance Spectroscopy 2Fulvestrant 2Doxorubicin 2ulixertinib 1tucatinib 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1trametinib 1selinexor 1sapanisertib 1sacituzumab govitecan 1relugolix 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1niraparib 1larotrectinib 1ipatasertib 1erdafitinib 1dostarlimab 1dehydroftorafur 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Neoplasms × 4-hydroxy-N-desmethyltamoxifen × 1 year × Clear all
NCT01273168 2025-12-23

Endoxifen in Adults With Hormone Receptor Positive Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
40 enrolled
BreastGynecologicSarcoma

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡